Treats thyroid eye disease regardless of thyroid eye disease activity or duration. BLA 761530, held by Viridian Therapeutics Inc. Veligrotug-Vvze.
As of Nov 13, 2026, BLA 761530 (Lumvoa), held by Viridian Therapeutics Inc, was first approved by FDA on Jun 26, 2026, with 0 approved supplements and 0 published complete response letters.
LUMVOA is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2026 | Original applicationNew molecular entity · Priority review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lumvoa500MG/10ML · injection | Veligrotug-Vvze | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
